The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

ConclusionsTime to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA –PFS.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research